Hard immunity must be achieved to protect against this hyperthermia. In other words, 60 to 70 percent of the people have to be vaccinated. This will require 25 crore doses of vaccine. Bangladesh has agreed to procure vaccines from a single source outside the multilateral venture Covax. The Seram Institute of India will administer 30 million doses of the vaccine. Of this, only 6 million vaccines have been received till February. 5 million vaccines were to be sent every month. In addition, India has donated 32 lakh doses of vaccine. India itself is now plagued by a deadly infection, which has led it to suspend vaccine exports since March 25. No dose has yet been received from Covax. The first dose of the vaccine has been discontinued since April 28.
The November 28 column, entitled “Vaccination for All Must Be Ensured,” called for ensuring vaccination for all to save lives and livelihoods through a multi-faceted initiative, including self-production of vaccines, multi-stakeholder distribution, and integrated distribution network.
The high transmission rate in India has made it difficult to strike a balance between domestic demand and contract exports. The Indian government has banned the export of vaccines due to the dire situation of the second wave. In this situation, Bangladesh is not getting vaccinated as per the agreement. Vaccination is being talked about through diplomatic pressure or negotiations. But even then, the chances of ensuring full supply at the right time are slim.
The company is dependent on the United States for raw materials. India has not been able to produce vaccines on demand due to US government restrictions on the import of vaccine raw materials. In addition, the company is talking about a shortage of funds. Although India’s Seram Institute has promised to produce the most vaccines, in reality the United States and China are doing just that. It is doubtful whether India will be able to meet its own needs as well as ensure supply for Covax as per the agreement. It is not advisable to rely solely on a single source.
Despite initial attempts to reach out to Russia, the government has not been able to find an alternative source of vaccine due to pressure or sectarian monopoly. Ticker now has a “confidentiality” agreement with Russia to obtain information on clinical trials and other matters. Now an overall agreement has to be reached through integrated bargaining. First, the agreement must be made in such a way that it can be implemented quickly through mutual trust. Second, the agreement must mention all three options. Ticker is imported directly, bottled here by bulk or bulk import and produced in the country jointly with Russia. Third, it must be multidimensional, so that the required dose of vaccine can be collected from all sources. Officially we have to move towards co-production. Arrangements must also be made to approve the vaccine on an emergency basis. At the same time, the standards must be maintained so that the people are not put at risk.
The International Center for Diarrhea Research (ICDDRB) applied for a clinical trial of the Chinese company Sinovec. The people did not get any official comment on why this initiative was not implemented. New initiatives have been launched with China on vaccination. In addition to Bangladesh, the Chinese platform ‘Emergency Vaccine Storage Facility for Cowid for South Asia’ includes Afghanistan, Pakistan, Nepal and Sri Lanka. Vaccination is an urgent matter of human health. It would not be wise to confuse geopolitics with this. Nor is it a repetition of previous events; It is important to move forward with education.
The World Health Organization (WHO) launched the COVAX program in the middle of last year to ensure the smooth and equitable distribution of vaccines around the world. Tickers have been promised for at least 20 per cent of the total population in each country this year. Under this program, only one-fifth of the Oxford-AstraZeneca vaccine that was supposed to be delivered by next May has been delivered so far. Big countries like Brazil and Indonesia have received only one-tenth of the promised vaccines as of May. Several countries including Bangladesh, Mexico, Myanmar and Pakistan have not received a single dose of vaccine. The African country of Rwanda received only 32 percent of the allocation; Niger, Kenya, Ethiopia and the Democratic Republic of Congo received 28 percent of the allocation. The time has come for rich countries to make fair demands for the provision of vaccines in the CoVAX program, aimed at multilateral justice. The Kovacs vaccine is not being supplied mainly due to export bans of producing countries and stockpiles of rich countries. Again, developing countries are not able to go into production on their own because the intellectual property rights of Ticker are not open. If the intellectual property is opened, it is possible to give this vaccine to 80% of the people of the world by this year and by 2022.
The consensus is that the world’s most at-risk countries will be vaccinated first, and the distribution will be balanced according to the framework set by the World Health Organization. But rich countries are reluctant to accept the structure of the World Health Organization. The Ticker Alliance failed to meet any conditions for the closure of the Gavy companies. Gavi has failed to ensure equitable distribution of vaccines, production, supply, pricing and fair receipt. Companies are setting exclusive prices. Vaccines invented in the public interest in the business interests of companies are not seen as a public asset. Developing countries have to buy vaccines at high prices. For example, Bangladesh is buying vaccines from India at a higher price than the European Union. Again purchase due to export ban t